As I recall, they were bringing spread sheet guys in from the dog and paying for them by cutting heads and compensation at Blue Links. They may be planning on going into the spreadsheet business and exiting lumber supplies.
Am I wrong? Is it delayed 6 months? Is there a black box that says only mice can take it? This is too funny folks, I advise hold on, this drug wins in the end and so do the longs. This is so silly.
Ripe for the picking. ZIOP is after the 90% of the market that is solid tumors. Solid tumors express “neoantigens” not CD19. ZIOP will be in the middle of the fight on solid cancers and may be at the front of the pack with the help of Cooper and MD Anderson.
Fighting Cancer With Killer T-Cells: 5 Developments To Watch. Forbes, April 21, 2016 "ZIOPHARM Who?"
Fighting Cancer With Killer T-Cells: 5 Developments To Watch. Forbes, April 21, 2016
Three companies are locked in a tight race to develop next-generation immuno-oncology treatments called chimeric antigen receptor T-cells (CARTs)—sophisticated, personalized medicines that use patients’ own cells to destroy their tumors: Juno Therapeutics, Novartis and Kite Pharma.
So all eyes were on those companies at the annual meeting of the American Association for Cancer Research (AACR), which wrapped up yesterday in New Orleans.
All three companies continue to report progress for CART therapies in treating blood cancers like leukemia and lymphoma. These treatments work by targeting a specific antigen, or protein, on the surface of cancer cells called CD19. T-cells are extracted from the blood of patients then re-engineered to home in on cancer cells bearing the antigen and kill them. The advantage of CD19 is that it’s widely prevalent in blood-borne cancer cells but not on normal tissues, making CARTs extremely precise weapons. Kite, Novartis and Juno have all told investors that if the trials stay on track, they could see their most advanced CARTs approved by the FDA as early as 2017. Less
No - the implication is that AAV treatments will fade over several years as cells die while ZF treatments will live for a lifetime as new treated cells are split off.
SAFETY: Two deaths were reported, neither of which were reported as study drug related. One was a 37-year-old male with a 10-year history of multiple surgeries for extrasellar pituitary macroadenoma. Six months after OOC initiation he had a suspected biliary obstruction, and subsequently also developed sepsis and multiple organ failure. At autopsy, no evidence for biliary obstruction was observed. The second was a 60-year-old male with cardiovascular risk factors, diagnosed with pancreatic cancer after six months into the study, and suffered a fatal myocardial infarction.